We thank Pruc and Szarpak [1] for their interest in our article [2]. They address several questions, nicely summarised in the last sentence of their letter, “future research should focus on the specific type of inhaled corticosteroids (ICS) used, risk factors for pneumonia, the influence of biomarkers, the effect of ICS on quality of life, drug-drug interactions, and the incorporation of non-pharmacological interventions to provide a more comprehensive and efficient treatment strategy”.
